| Contract Development and Manufacturing Operations (CDMO) | End-to-end development and manufacturing of biologics, sterile injectables, drug-device combos, and softgel capsules. | Five global manufacturing sites, strong regulatory approvals, diversified modality expertise, long-term customer relationships. | Global pharmaceutical companies including small biotechs, generic firms, and innovators (B2B). | Biologics CDMO and drug-device combination development have highest margins. | 1445 | 100 | Revenue from contract manufacturing agreements, development services, and licensing fees. | Contract-based revenue with long-term supply and development agreements. | Growth in biologics, injectables, increasing outsourcing by pharma, and capacity expansions driving segment growth. | Biologics CDMO, Injectable Solutions, Drug-Device Combinations (DDC), Soft Gelatin Capsules |
